
News|Articles|October 13, 2025
Prescription Access Crisis: 40% of GLP-1 RA Rx Are Unfilled
Author(s)Maggie L. Shaw
Fact checked by: Skylar Jeremias
A recent study reveals significant barriers to GLP-1 RA access for diabetes and obesity patients, highlighting racial disparities and high costs.
Advertisement
Advertisement
An alarming 40% of orders for glucagon-like peptide-1 receptor agonists (GLP-1RAs) went unfilled between January 2018 and September 2022, according to a new study from the University of Colorado Health (UCHealth) system, with patients citing soaring costs, insurance roadblocks, and potential prejudicial prescribing behavior because of race as access barriers.1 In addition, despite a higher prevalence of
Related to this article

Liver disease disparities tied to insurance and race spanned HCC surveillance, transplant listing, and drug access in data at The Liver Meeting 2026.

This week in health equity and access: Medicaid cuts; mailed FIT outreach; EEOC pregnancy rules; GLP-1 Bridge access; and 2027 policy shifts.

A prospective Italian study of 492 postmenopausal women found ultrasound signs of deep endometriosis in 7.3%, often plaque-like and poorly vascularized.

AHIP's Jeanette Thornton explains where 2027 prior authorization standards fit in the affordability debate and what plans want from Congress.

The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.

In this Q&A, Rob Stransky of NiceRx explains how to screen patients for gray-market retatrutide use and why cost drives demand for unregulated peptides.

SCOUT-HCM 56-week data show sustained LVOT gradient reductions with mavacamten and no LVEF below 50% in adolescents with obstructive HCM.
Advertisement
Advertisement

